Description: Modified GRF 1-29, also known as GHRH (1-29), is a growth hormone-releasing hormone (GHRH) analog that may be used as a diagnostic agent.
It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, and is thought to be the shortest fully functional fragment of GHRH. It is used as a diagnostic agent to assess growth hormone (GH) secretion.
It is also used as a doping agent in sports due to its correlation with increased growth of muscular and skeletal tissue.
Modified GRF (1-29) is also hypothesized to improve deep rapid eye movement sleep.
Buy Modified GRF 1-29 (CJC-1295 No DAC)
Modified Growth Releasing Factor 1-29 replaces 15 amino acids and exchanges 1, 2, 3, or 4 of the remaining amino acids.
Therefore, it results in a modified GHRH with 29 amino acids, giving the cause behind the name Mod Growth Releasing Factor 1-29.
GHRH (1-29) has many different forms, and there are several ways to modify the structure.
One study has tested 30 of these analogs with one or more of these forms being effective over others, yet all analogs of GHRH stimulate growth hormone GH from the pituitary gland effectively.
Enhanced growth hormone levels give rise to insulin-like growth factor levels.
Modified Growth Releasing Factor amino 1-29, is also called as Modified GRF 1-29 and also known as CJC-1295 without DAC that causes GH secretion.
CJC-1295 no DAC is a synthetic analog of the endogenous peptide signalling hormone. Growth Hormone Releasing Hormone (GHRH).
Endogenously produced GHRH has 44 amino acids in its chain structure. A truncated synthetic form of GHRH called Sermorelin has 29 amino acids.
Modified Growth releasing Factor (1-29) is further changed in that it has four substituted amino in its chain that serves the purposes of preventing degradation and oxidation in manufacture and transport as well as in vivo, while also increasing binding affinity to the GHRH receptors for GH releasing effect.
The concurrent use of GHRH and growth hormone releasing peptides such as GHRP-2, GHRP-6, Ipamorelin, and Hexarelin multiply growth hormone secretion much more than anyone on its own.
Modified GRF (1-29) is not CJC-1293, nor should it be referred to as such. Modified GRF (1-29) is identical to the portion of CJC 1295 DAC (The long-acting analog) that is not bound to MPA, minus the lysine.
The presence of lysine in a literal “CJC without DAC” in the absence of MPA would have the opposite effect of DAC: it would drastically reduce the active life of the peptide to that of Sermorelin.
Modified GRF (1-29) is the same as CJC-1295 without DAC.
Tetrasubstituted GRF (1-29)
Being a GHRH analog, Modified GHRH (1-29) most significant use is in raising hGH levels. And it does precisely that.
Across the board buy CJC-1295 no DAC as it is proven to effective at raising hGH and IGF-1 levels in the body.
Human growth hormone and insulin-like growth factor 1 are the primary growth hormones used to build muscle, repair injuries, and support all around health.
It is well proven as a GHRH replacement in animals and humans and works as an injection or intranasally.
This Product is intended for laboratory research purposes only.
The name Mod GRF 1-29 was initially derived by a researcher known as DatBtrue, who coined the term in his internet publicized articles on the substance.
Because of the popularity of his articles, the new name quickly adopted by readers, and the frequent use of the name spread wildly from there. However, perhaps the most common name for this substance is CJC-1295 without DAC.
The importance of understanding the difference in these names is the history of the substance and its structure.
Mod GRF 1-29 belongs to a category of peptides known as HGH (Human Growth Hormone) secretagogues.
It is a modified derivative of an already existing derivative of Growth Hormone Releasing Hormone (GHRH), which is an endogenously produced peptide hormone in the human anterior pituitary.
Therefore, it could be referred to more appropriately as a second-generation derivative of GHRH. GHRH is modified to create what is known as Growth hormone Releasing Factor (GRF) 1-29. GRF 1-29 is then further modified to create Mod GRF 1-29.
The nomenclature of the evolution of the derivatives should be self-explanatory concerning this. GRF 1-29 is also known by its trade name, Sermorelin (which Mod GRF 1-29 is a derivative of).
The most popular name for this peptide, however, is CJC-1295 without DAC and is referred to as such because there is a third derivative of GHRH.
CJC-1295 with DAC, the acronym DAC stands for Drug Affinity Complex, which is a modification that is added to the peptide that extends its half-life and active life in the body.
When one buys CJC-1295 without DAC, it is simply Mod GRF 1-29.
For ease of explanation and clarification to the reader, what has been discussed thus far is the following:
GRF 1-29 is a modification of GHRH (Growth Hormone Releasing Hormone)
Mod GRF 1-29 is a modification of GRF 1-29
CJC-1295 with DAC is a modification of Mod GRF 1-29
Now that the complex naming system has been clarified, the general description of Mod GRF 1-29 is as follows:
Mod GRF 1-29 is a peptide hormone (also known as a protein hormone) that was developed in Canada and first mentioned in medical literature in 2005. It is a protein that is 29 amino acids long, and as explained earlier, it is a GHRH analog.
As a GHRH analog, Mod GRF 1-29 (CJC-1295 without DAC) acts on receptors at the pituitary gland to stimulate the release of Human Growth Hormone.
To understand its function and what it is, one must understand the concept behind the protein/peptide structure of these hormones (which will also consequently help the reader to understand further the difference in the naming that has been discussed above).
Chemical Characteristics of Modified GRF 1-29 (CJC-1295 No DAC)
Proteins/peptides are chains of amino acids linked in specific different orders. Proteins, depending on how many amino acids it is composed of, will manifest itself as one of three structural types:
the primary protein structure, which is simply a long chain of amino acids, the secondary protein structure, which is a folded protein structure resembling a pleated sheet.
The tertiary protein structure is a complex fold of proteins that resembles a tangled ball of yarn, and finally, the quaternary protein structure which is several tertiary proteins interconnected.
The significance of this in protein hormones such as Human Growth Hormone (HGH), insulin, Luteinizing Hormone (LH), Mod GRF 1-29 (CJC-1295 without DAC).
The fact is various sections of the protein structure will contribute to different jobs in the body by binding to and activating different receptors.
The shape of the peptide hormone, and the different subsections of it can allow stronger binding affinity or weaker binding affinity.
Growth Hormone Releasing Hormone (GHRH), which is the endogenously secreted GHRH by the arcuate nucleus of the hypothalamus of the human body, is 44 amino acids long.
It was discovered, however, that only the first 29 amino acids of the protein were equally as effective in binding to receptors on the pituitary gland as the full 44 amino acid structure.
The first 29 amino acids in its protein structure were then isolated, which was then called GRF 1-29, but the problem with this derivative of GHRH was the fact that it was rapidly metabolized and cleared from the body by enzymes.
Studies have reported that GRF 1-29’s half-life is less than 10 minutes and as little as 5 minutes.
This was obviously not enough time to ensure a maximized and sustained release of HGH from the pituitary gland, as studies have demonstrated that the full potential of an HGH pulse from the pituitary requires at least 30 minutes as evidenced by the fact that much higher HGH levels (50 times greater) were observed 15 – 30 minutes into subcutaneous administration of GHRH analogs
Name: modified GRF (1-29) acetate
CAS#: 114466-38-5 (acetate); 86168-78-7 (free base).
Chemical Formula: C151H250N44O44S
Molecular Weight: 3417.985
Elemental Analysis: C, 53.06; H, 7.37; N, 18.03; O, 20.60; S, 0.94
This product is sold only to qualified and trained individuals who can handle it safely. This peptide is only to be used in academic or laboratory research without exception.